公开(公告)号：US20250163470A1

公开(公告)日：2025-05-22

申请号：US19023648

申请日：2025-01-16

Applicant: UCL BUSINESS LTD

Inventor： Thomas Voit ,  Julie Dumonceaux ,  Perry Elliott ,  Virginie Mariot

IPC: C12N15/86 ,  A61K48/00

Abstract: Disclosed are a composition and method of treating or preventing cardiomyopathy in a human subject. In some embodiments, the method comprises delivering a therapeutic dose of a gene therapy vector to cardiomyocytes of the human subject, wherein the gene therapy vector comprises a nucleic acid sequence encoding for PKP2.

公开(公告)号：US20220389452A1

公开(公告)日：2022-12-08

申请号：US17761677

申请日：2020-09-21

Applicant: UCL BUSINESS LTD

Inventor： Thomas Voit ,  Julie Dumonceaux ,  Perry Elliott ,  Virginie Mariot

IPC: C12N15/86

Abstract: Disclosed are a composition and method of treating or preventing cardiomyopathy in a human subject. In some embodiments, the method comprises delivering a therapeutic dose of a gene therapy vector to cardiomyocytes of the human subject, wherein the gene therapy vector comprises a nucleic acid sequence encoding for PKP2.

公开(公告)号：US20240076696A1

公开(公告)日：2024-03-07

申请号：US18503557

申请日：2023-11-07

Applicant: UCL BUSINESS LTD

Inventor： Thomas Voit ,  Julie Dumonceaux ,  Perry Elliott ,  Virginie Mariot

IPC: C12N15/86

CPC classification number: C12N15/86 ,  A61K48/00

Abstract: Disclosed are a composition and method of treating or preventing cardiomyopathy in a human subject. In some embodiments, the method comprises delivering a therapeutic dose of a gene therapy vector to cardiomyocytes of the human subject, wherein the gene therapy vector comprises a nucleic acid sequence encoding for PKP2.

公开(公告)号：US20240042059A1

公开(公告)日：2024-02-08

申请号：US18282061

申请日：2022-03-18

Applicant: UCL BUSINESS LTD

Inventor： Thomas Voit ,  Julie Dumonceaux ,  Perry Elliott ,  Virginie Mariot

IPC: A61K48/00 ,  C12N15/86 ,  A61K38/17 ,  A61P9/04

CPC classification number: A61K48/0058 ,  C12N15/86 ,  A61K38/1709 ,  A61K48/0041 ,  A61P9/04 ,  C12N2750/14143 ,  C12N2750/14145

Abstract: Disclosed are a composition and method of treating or preventing cardiomyopathy in a human subject. In some embodiments, the method comprises delivering a therapeutic dose of a gene therapy vector to cardiomyocytes of the human subject, wherein the gene therapy vector comprises a nucleic acid sequence encoding for PKP2.